More on BAYRY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $12.26 |
|
|||
| Open | $12.14 | ||||
| 52 Wk High | $135.54 | ||||
| 52 Wk Low | $94.36 | ||||
| Day High | $12.15 | ||||
| Day Low | $11.87 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,002,981 | ||||
- Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
- Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
- FDA accepts Bayer's application to expand Kerendia to CKD without diabetes
- U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
- Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
- Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
- MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
- FDA grants priority review to Bayer's Lynkuet for breast cancer use
- U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related
- Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
Entities mentioned with BAYRY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Credit Suisse | View Related Stories »
- Show More...
